Verbatim response from Perplexity
The most reputable compounded GLP-1 programs right now appear to be the ones that emphasize transparent pricing, licensed clinician oversight, and use of accredited/credentialed pharmacies. Based on the available rankings, the strongest names to look at are FormBlends, Eden, ShedRx, Trimi, Mochi Health, Henry Meds, and Ro.[3][4][1]
Best options by reputation signal
- FormBlends — ranked highest in one review because it scored best on third-party testing, pharmacy credentials, transparent pricing, and no FDA warnings.[3]
- Eden — consistently placed near the top for safety/transparency and was rated highly in multiple rankings.[3][2]
- ShedRx — stood out for flat pricing, multiple formats, and a strong safety score in one 2026 ranking.[3]
- Trimi — praised for named 503A pharmacy partners, clinician-guided care, and all-in pricing.[4]
- Mochi Health — widely listed among top programs and noted for LegitScript certification in one ranking.[3][1]
- Henry Meds — frequently appears in top lists and is a large, established telehealth brand, though one source flags a weak BBB rating.[1][3]
- Ro — a major telehealth brand with its own pharmacy infrastructure, which helps with consistency and oversight.[4]
How I’d interpret the market
- If you want the best reputation for safety/transparency, the strongest signals in the sources point to FormBlends, Eden, and ShedRx.[3]
- If you want a larger, more established consumer brand, Ro, Hims & Hers, and Henry Meds are the most recognizable names in the lists.[1][4]
- If you want the most cautious choice, several rankings stress picking programs that use accredited 503A pharmacies, publish batch testing/COAs, and avoid vague sourcing claims.[3][4]
Programs I’d be more careful about
- Any provider with an F BBB rating or unclear sourcing deserves extra scrutiny; one ranking specifically noted Henry Meds carries an F BBB rating despite being included for transparency.[3]
- Rankings that are based mostly on editorial scoring can conflict, so reputation should be judged by pharmacy quality, clinician oversight, and transparency, not just placement on a list.[1][2][3][4]
If you want, I can turn this into a shortlist by budget like “best overall,” “best low-cost,” and “best safest pick.”